Rheumatoid Arthritis
Conditions
Interventions
Trade Name: rosuvastatin
Product Name: rosuvastatin
Product Code: ZD 4522
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Rheumatoid Arthritis of > 5 years, CRP > 10mg/l, ESR > 25 mm/hr or PV > 1.78 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients on cyclosporine or other medications known to be contraindicated. Symptomatic vascular diseases. Subejects with a total cholesterol of >7.5 mmol/l Any known contra-indication to rosuvastatin as per the product information. Diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Rosuvastatin 10 mgs/day is more effective than placebo in improving vascular markers for future cardiovascular events in patients with chronic RA. ;Secondary Objective: The anti-inflammatory effects of the rosuvastatin are seen in the active group as measured by inflammatory markers and joint inflammation.;Primary end point(s): Blood tests for Vascular markers and inflammation Clinical measures of joint disease activity Non-invasive Vascular tests | — |
Countries
United Kingdom
Outcome results
None listed